Aktie A0M38C JIANGSU WUZHONG PHARMACEUTICAL DEVELOPMENT CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen JiangSu WuZhong Pharmaceutical Development Co., Ltd.

Aktien

A0M38C

CNE000000YP4

600200

Schlusskurs Shanghai S.E.
Andere Börsenplätze
 00:00:00 20.05.2024 		% 5 Tage % 1. Jan.
11.23 CNY +2.65% Intraday Chart für JiangSu WuZhong Pharmaceutical Development Co., Ltd. +6.24% +36.62%
24.04. JiangSu WuZhong Pharmaceutical Development Co., Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI
24.04. JiangSu WuZhong Pharmaceutical Development Co., Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
JiangSu WuZhong Pharmaceutical Development Co., Ltd. cancelled the transaction announced on April 25, 2023
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Jiangsu WuZhong Pharma to Invest 30 Million Yuan in Local Biotech Firm
Wuzhong Pharmaceutical Development's Unit Gets Registration Certificate for Linezolid Sodium Chloride Injection
JiangSu WuZhong Pharmaceutical Development Co., Ltd.(XSSC:600200) added to S&P Global BMI Index
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
JiangSu WuZhong Pharmaceutical Development Co., Ltd. cancelled the transaction announced on November 11, 2021
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
JiangSu WuZhong Pharmaceutical Development Co., Ltd. announced that it expects to receive CNY 1.2 billion in funding from Zhejiang Fuji Holdings Group Co., Ltd. and other investors
Cinkate Medicine Chemical Intermediate Co., Ltd. agreed to acquire 15% stake in Suzhou Changzheng Cinkate Pharmaceutical Co., Ltd. from JiangSu WuZhong Pharmaceutical Development Co., Ltd. for CNY 33 million.
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
JiangSu WuZhong Pharmaceutical Development Co., Ltd. cancelled the transaction to acquire 70% stake in Shanghai Weina Cosmetics Co., Ltd., from Weina Hongkong Co., Limited.
Jiangsu Wuzhong Pharmaceutical Group Corporation announced that it expects to receive CNY 340 million in funding from JiangSu WuZhong Pharmaceutical Development Co., Ltd.
JiangSu WuZhong Pharmaceutical Development Co., Ltd. announced that it expects to receive CNY 300 million in funding from Suzhou Fuji Suwu Pharmaceutical Technology Partnership Enterprise (Limited Partnership)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A0M38C Aktie
  4. Nachrichten JiangSu WuZhong Pharmaceutical Development Co., Ltd.
  5. Andere Sprachen